PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics 7th May 2025
PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes 10th September 2024
PhoreMost Achieves Second Milestone in Target Discovery Alliance with Boehringer Ingelheim 3rd June 2024
PhoreMost appoints Professor Peter Parker and Dr Jason Imbriglio to Scientific Advisory Board 17th July 2023
PhoreMost Reaches Milestone in a Target Discovery Alliance with Boehringer Ingelheim 5th January 2023